APLINDORE
Aplindore is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | APLINDORE |
| INN | aplindore |
| Description | Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.
|
| Classification | Small molecule |
| Drug class | dopamine D2D3 receptor modulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1Cc2c(ccc3c2O[C@@H](CNCc2ccccc2)CO3)N1 |
Identifiers
| PDB | — |
| CAS-ID | 189681-71-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2110659 |
| ChEBI ID | — |
| PubChem CID | 6440763 |
| DrugBank | DB06620 |
| UNII ID | Q5O76TA0ML (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use